{{Drugbox
| verifiedrevid = 464392221
| IUPAC_name = (''R'')-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-''a'']pyrazin-7(8''H'')-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
| image = Sitagliptin.svg
| width = 254
| image2 = Sitagliptin 3D.png
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|januvia}}
| MedlinePlus = a606023
| licence_EU = Januvia
| licence_US = Sitagliptin
| pregnancy_AU = B3
| pregnancy_US = B
| legal_AU = S4
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = 口服
<!--Pharmacokinetic data-->
| bioavailability = 87%
| protein_bound = 38%
| metabolism = [[肝脏|肝脏]] ([[CYP3A4|CYP3A4]]- 和[[CYP2C8|CYP2C8]]-mediated)
| elimination_half-life = 8到14小时<ref name=Herman>{{cite journal | author = Herman GA | coauthors = Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA | title = Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses | url = https://archive.org/details/sim_clinical-pharmacology-and-therapeutics_2005-12_78_6/page/675 | journal = Clin Pharmacol Ther | volume = 78 | issue = 6 | pages = 675–88 |date=December 2005 | pmid = 16338283 | doi = 10.1016/j.clpt.2005.09.002}}</ref>
| excretion = [[肾脏|肾脏]] (80%)<ref name=Herman/>
<!--Identifiers-->
| IUPHAR_ligand = 6286
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 486460-32-6
| ATC_prefix = A10
| ATC_suffix = BH01
| PubChem = 4369359
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01261
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3571948
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = QFP0P1DV7Z
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 40237
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1422
<!--Chemical data-->
| C=16 | H=15 | F=6 | N=5 | O=1
| molecular_weight = 407.314 [[Gram|g]]/[[Mole_(unit)|mol]]
| smiles = Fc1cc(c(F)cc1F)C[C@@H](N)CC(=O)N3Cc2nnc(n2CC3)C(F)(F)F
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MFFMDFFZMYYVKS-SECBINFHSA-N
}}
'''西格列汀（{{lang-en|Sitagliptin}}）'''，商品名为'''佳糖維'''，是一种口服降糖药（[[抗糖尿病药|抗糖尿病药]]），属于[[二肽基肽酶-4抑制剂|二肽基肽酶-4（DPP-4）抑制剂]]，由[[默克公司|默克公司]]研发和销售。西格列汀可以单独应用也可以与其他口服降糖药组成复方药物（如[[二甲双胍|二甲双胍]]或[[噻唑烷二酮|噻唑烷二酮]]）来治疗[[2型糖尿病|2型糖尿病]]。<ref name=medupdate01>{{cite web |title=Sitagliptin for Type 2 Diabetes |author=National Prescribing Service |date=August 2010 |accessdate=27 August 2010 |url=http://www.nps.org.au/consumers/publications/medicine_update/issues/sitagliptin |deadurl=yes |archiveurl=https://web.archive.org/web/20100718022620/http://www.nps.org.au/consumers/publications/medicine_update/issues/sitagliptin |archivedate=2010年7月18日 }}</ref> 西格列汀的优点是控制血液中葡萄糖含量时副作用更少（如更低几率导致低血糖和体重增加）。虽然安全性是它的优势，但是效果并不能得到很好的保证，所以一般推荐与其他药物合用如[[二甲双胍|二甲双胍]]。

==引用==
{{reflist}}
{{口服降糖药和胰岛素类似物}}
[[Category:酰胺|Category:酰胺]]
[[Category:有机氟化合物|Category:有机氟化合物]]

{{MSD}}